- The companies reported the initiation of a P-II dose-finding study assessing the safety, reactogenicity, and immunogenicity of two injections given 21 days apart in 720 adults aged ≥18yrs.
- The P-II study assesses the potential for refined antigen formulation to achieve an optimal immune response, including in older adults. If P-II results are positive, the P-III study is expected to be initiated in Q2’21 with vaccine anticipated to be available in Q4’21
- In parallel to the P-II study, Sanofi has commenced development work against new variants, which will be used to inform the next stages of the Sanofi/GSK development program
Click here to read full press release/ article | Ref: Sanofi | Image: BioSpace